Mumbai, Sept 17 (ANI/Business Wire India) — Halma India, the Mumbai-based hub office of Halma p.l.c., has appointed Mahadev Dhuri as India sales manager for two of its ophthalmic companies, Keeler Limited and Volk Optical Inc.
The two companies are world leaders in their respective fields. Keeler, based in the UK, manufactures products such as direct and indirect ophthalmoscopes, non-contact tonometers and slit lamps, while Volk Optical, based in the USA, is a specialist in patented double aspherical optics.
Based in Mumbai, Mahadev will serve Keeler and Volk customers and distributors throughout India, offering educational and sales support for both companies’ complete product lines.
He will work closely with doctors and facilities to help them select, use and install diagnostic, therapeutic, and surgical ophthalmic instruments and accessories to facilitate the growth of ophthalmology in India.
He will also continue to develop the Indian distributor networks, training new and existing distributors, and increasing the company’s conference and tradeshow presence.
Mahadev, a trained biomedical engineer, joins Halma from Toshbro Medicals, a leading Indian specialist selling German and US medical instrumentation equipment into India.
Prior to that he spent eight years with Larsen and Toubro Limited developing the company’s medical equipment business across western, central and northern India. (ANI)
Sanofi, Piramal proposed merger deal falls through – report
A proposed deal by France’s Sanofi-Aventis to buy a majority stake in Indian drug maker Piramal Healthcare Ltd has fallen through due to differences over valuation, a newspaper reported on Monday.
In Februray, a source familiar with the situation had told Reuters that GlaxoSmithKline Plc and Sanofi-Aventis were bidding for the Indian drug maker, with the sale price perhaps going as high as $1.5 billion.
Mumbai-based Piramal has repeatedly denied acquisition reports, calling them ‘unfounded’, and has said the founder has no intention of diluting current ownership levels.
“Sanofi Aventis had put a valuation of over 300 rupees per share for Piramal Healthcare. But, this price was not acceptable to the promoters,” The Economic Times newspaper quoted a merchant banker familiar with the development as saying.
Talks between the two companies had reached an advanced stage before it collapsed, the paper said, citing another senior pharma industry official briefed about the proposed deal.
A Piramal spokesman declined comment while Sanofi-Aventis officials could not be reached for comments immediately.